Vitamin K antagonists have been used for many years as the treatment of choice for long-
term oral anticoagulation in patients with non-valvular atrial fibrillation. Unfortunately, the …

Background and Purpose—The use of vitamin K antagonists (VKAs), the cornerstone
treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived …

In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists
reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations …

Background: Recent observational studies have compared effectiveness and safety profiles
between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with …

Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

The aim of our article is to provide a concise review for clinicians entailing the main studies
that evaluated the efficacy and safety of target-specific oral anticoagulants (TSOAs) for …

Background Non‐vitamin K antagonist oral anticoagulants (NOAC s) are broadly preferable
to vitamin K antagonists (VKA s) for stroke prevention in non‐valvular atrial fibrillation (AF) …

Aims The introduction of non-VKA oral anticoagulants (NOACs), which differ from the earlier
vitamin K antagonist (VKA) treatments, has changed the approach to stroke prevention in …

Worldwide there is a tremendous need for affordable anticoagulants that do not require
monitoring. The advent of the non-warfarin oral anticoagulant drugs represents a major …

Aims The well-known limitations of vitamin K antagonists (VKA) led to development of new
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …